ArticlePloS one2016
Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Prevalence of sarcopenia in COPD patients using AWGS criteria among Asian populations: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Chronic Obstructive Pulmonary Disease and the Management of Cardiopulmonary Risk in the UK: A Systematic Literature Review and Modified Delphi Study.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Supplemental oxygen for symptomatic relief in people with serious respiratory illness: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- The Cost-Effectiveness of Pulmonary Rehabilitation for COPD in Different Settings: A Systematic Review.Applied health economics and health policy · 2021Pooled it
- Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review.International journal of environmental research and public health · 2020Pooled it
- The global impact of Aspergillus infection on COPD.BMC pulmonary medicine · 2020Pooled it
- The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Pooled it
- Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.International journal of chronic obstructive pulmonary disease · 2020Pooled it
- Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT.Health technology assessment (Winchester, England) · 2025Trial
- Periodontal status and lung function decline in the community: the Hisayama study.Scientific reports · 2018Trial
- Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.Seminars in respiratory and critical care medicine · 2026Review
- Cost-Effectiveness of Internet of Things-Based Management of Home Noninvasive Positive Pressure Ventilation in Patients With Chronic Obstructive Pulmonary Disease and Hypercapnic Chronic Respiratory Failure: Trial-Based Economic Evaluation.JMIR mHealth and uHealth · 2026Article
- Article
- Development and validation of a machine learning-based model to predict the risk of hospitalization death in hospitalized patients with AECOPD.Scientific reports · 2025Article
- Development of a healthcare utilisation index to compare patients worldwide: a cross-sectional study.BMC health services research · 2025Article
- Who "Needs" Long-Term Oxygen? How Little We Really Know.Annals of the American Thoracic Society · 2025Article
- Treatment patterns for chronic obstructive pulmonary disease under the tiered medical system.Scientific reports · 2025Article
- Article
- Industry 4.0-Compliant Occupational Chronic Obstructive Pulmonary Disease Prevention: Literature Review and Future Directions.Sensors (Basel, Switzerland) · 2024Review
- 2023 Year in Review: Home Oxygen Therapy.Respiratory care · 2024Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.
methodsThis cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.
resultsThe annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.
conclusionsThe economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.